extracellular domain (ECD) and the transmembrane domain (TM) of Her-2/neu, but not the intracellular domain (ICD) of Her-2/neu, and GM-CSF to a mammal in need of treatment of a Her-2/neu-over-expressing human cancer, thereby treating said Her-2/neu-over-expressing human cancer. ...
4ICD: Intracellular domain of HER4 AI: Aromatase inhibitor BC: Breast cancer CI: Confidence interval CYT: Cytoplasmatic domain DFS: Disease-free survival ER: Estrogen receptor HER: Human epidermal growth factor-related receptor HR: Hazard ratio JM: Juxtamembrane OS: Overall survival...
Her-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999;112(suppl 1):S53-S67. * 赫赛汀?作为全球第一种获准应用于临床治疗实体瘤的单克隆抗体,为HER2癌基因阳性的肿瘤患者带来了新的希望,不仅显著改善HER2阳性患者的生存率达45%,而且疗效改善持续,维持病人生活质量。 基因...
Methods: We use a splice-switching oligonucleotide (SSO) to direct the alternative splicing of HER4 from the CYT1 to the CYT2 isoform in HER4-expressing breast cancer cells. Results: Treatment with a target-specific SSO was accompanied by a decreased growth of the cells (Po0.0001). In ...
and Molecular Biology, Tulane University, New Orleans, LA, USA; 2Department of Pathology, University of Colorado Denver, Aurora, CO, USA and 3School of Medicine, Tulane University, New Orleans, LA, USA Experimental and clinical data support a growth inhibitory role for HER4 in breast cancer....
HER-2基因编码分子量为185kD的跨膜糖蛋白,即HER-2受体或称p185,是一种酪氨酸激酶受体,属于表皮生长因子受体家族的一员。它由胞外结构域(ECD)、跨膜结构域和细胞内结构域(ICD)三部分组成,其中胞外域(皿R_2ECD)可从完整的HER.2受体上被降解释放到外周血中并能被检测到‘21。研究表明18%一20%乳腺癌患者...
(or 2 if they were a certain age when they had them) because some people can have a temporary rise in their titre levels after one dose but it doesn’t offer them life long immunity. The current thinking on vaccinations is that once you have had your course in child hood you are ...
HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer. J. Mammary Gland Biol. Neoplasia 13, 247–258. https://doi.org/10.1007/s10911-008-9076-6 (2008). Article PubMed PubMed Central Google Scholar McGranahan, N. & Swanton, C. Clonal heterogeneity ...
The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER family genes in early breast cancer, as well as to investigate the predictive value of HER2 mRNA expression for adjuvant treatment with paclitaxel. RN
The design of cancer immunotherapies and vaccines has benefited greatly from the identification of tumor-associated antigens. One such antigen, HER-2/Neu, is a prime target for such strategies due to its amplification in a variety of cancers, including breast and ovarian cancer. The HER-2/Neu...